30 citations
,
September 2017 in “Environmental health perspectives” This study found that potential exposure to Corexit™ dispersants during the Deepwater Horizon cleanup was associated with increased respiratory, dermal, and eye irritation symptoms among responders both during the cleanup and up to three years later.
September 2023 in “Journal of the American Academy of Dermatology” Certain factors like being female, having high cholesterol, using Medicaid, and previous non-biologic treatments increase the risk of multiple biologic failures in psoriasis patients.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
September 2023 in “Journal of the American Academy of Dermatology”
November 2017 in “Asian journal of pharmaceutical and clinical research” This study predicted that 6-hydroxy genistein, coreximine, and scoulerine from Dadap leaves may act as anti-alopecia agents by interacting with JAK2, but further in-vivo testing is needed.
February 2023 in “Reactions Weekly”
This study suggests that while alopecia areata presents similarly across different skin tones, hair loss may be underestimated in individuals with more tightly coiled hair without a comprehensive examination, highlighting the need for culturally sensitive evaluation approaches, particularly for Black women.
January 2025 in “SKIN The Journal of Cutaneous Medicine” People with alopecia areata face different healthcare access and experiences based on their race and ethnicity.
November 2025 in “SKIN The Journal of Cutaneous Medicine” This review highlights the significant psychosocial impact of alopecia areata on children and adolescents, affecting self-esteem, relationships, academic performance, and the well-being of their families.
July 2025 in “SKIN The Journal of Cutaneous Medicine” This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.
September 2024 in “Cutis” This study reached a consensus among experts on the most important diversity, equity, and inclusion topics for dermatology residency curricula, suggesting integration may enhance patient care for diverse populations.
July 2024 in “Reactions Weekly” This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.
March 2002 in “Clin-Alert” In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” This study found that 4-(ethoxycarbophenyl) retinamide (RI) exhibited significantly lower acute, subacute, and chronic toxicity compared to other retinoids in mouse and rat models.
March 2019 in “Reactions Weekly” May 2011 in “Psychiatric News” This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.
January 2023 in “Reactions Weekly” March 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
June 2019 in “Poster presentations” This study found that patients with rheumatoid arthritis who discontinued and restarted methotrexate had less improvement in disease activity, more side effects, and more initial comorbidities than those who persisted on the therapy.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly”
July 2016 in “Dermatologie pro praxi” This article discusses the use of Espumil foam base in pharmacies for preparing dermatological medications and reports no new clinical results.